Fudan University: Neoplasm Metastasis trials

The registry lists 65 Neoplasm Metastasis studies with Fudan University as lead sponsor. 32 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 28Phase 3 11Phase 4 6No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)RecruitingNCT07815834Phase 3
• The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07780578Phase 2
• A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast CancerRecruitingNCT07653893
• Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic MalignanciesRecruitingNCT07459309Not applicable
• Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal CancerRecruitingNCT06934018Not applicable
• Tamoxifen for Advanced Solid Pseudopapillary Tumor of the PancreasRecruitingNCT06914674Phase 2
• A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Recurrence of Colorectal Cancer After Complete Resection of Peritoneal MetastasesRecruitingNCT06903325
• BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCRecruitingNCT06793332Phase 2
• Study of HRS-2189 Combined HRS-5041 in Prostate CancerNot yet recruitingNCT06738745Phase 2
• Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingNCT06718933Phase 1/2
• Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung CancerRecruitingNCT06684418
• Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal CancerNot yet recruitingNCT06593548Phase 2
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain MetastasisRecruitingNCT06501391Phase 2
• clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone MetastasesRecruitingNCT06392217
• WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain MetastasesRecruitingNCT06243003Phase 1/2
• SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain MetastasesNot yet recruitingNCT06210438Phase 2
• Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics ModelRecruitingNCT06202404
• Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally RecurrenceRecruitingNCT06120127Phase 2
• Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine MonotherapyRecruitingNCT06090994Phase 4
• A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain MetastasesNot yet recruitingNCT06088056Phase 2
• Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLMNot yet recruitingNCT05948072Phase 3
• Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidednessNot yet recruitingNCT05881746Not applicable
• Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisNot yet recruitingNCT05860907Phase 4
• Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesRecruitingNCT05771025Not applicable
• A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal MetastasisNot yet recruitingNCT05359393Phase 2
• Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver MetastasisNot yet recruitingNCT05354674
• Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid TumorsRecruitingNCT05098847Phase 2
• Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)RecruitingNCT05094882
• Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast CancerRecruitingNCT04947280Phase 1/2
• FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver MetastasesRecruitingNCT04832776Phase 2
• mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited MetastasesRecruitingNCT04781270Phase 3
• Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver MetastasesRecruitingNCT04687631Phase 3
• Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal MetastasisActive, not recruitingNCT07079462Phase 2
• Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver MetastasesCompletedNCT06023173
• Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis PatientStatus unknownNCT05873972Not applicable
• Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II StudyStatus unknownNCT05753163Phase 2
• Anatomical Resection in Colorectal Liver Metastases PatientsCompletedNCT05673564
• Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver MetastasisCompletedNCT05462470
• Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyActive, not recruitingNCT05435313Phase 2
• Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA TrialStatus unknownNCT05188911
• Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05095636Phase 2
• ARX788 in HER2-positive Breast Cancer Patients With Brain MetastasesStatus unknownNCT05018702Phase 2
• Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver MetastasisStatus unknownNCT04912258Phase 3
• Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain MetastasesStatus unknownNCT04582968Phase 1/2
• Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver MetastasesStatus unknownNCT04525326Phase 3
• The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM PatientsStatus unknownNCT04525313
• Cetuximab Re-challenge for Colorectal Cancer Liver MetastasisStatus unknownNCT04509635Phase 3
• FSRT in Breast Cancer Patients With Brain MetastasesStatus unknownNCT04061408Phase 2
• Use of Plasma ctDNA Methylation Haplotypes in Detecting Local Residual or Lymph Node MetastasisStatus unknownNCT03868215
• CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRCStatus unknownNCT03725254Phase 2
• A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNAStatus unknownNCT03679039
• Peritoneal Lavage for Early Detecting Gene Mutation of Peritoneal Metastasis of Gastric CancerCompletedNCT03314649
• Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLMStatus unknownNCT03127072Phase 4
• Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver MetastasisStatus unknownNCT02631564
• Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer PatientsStatus unknownNCT01322178Phase 2
• New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited MetastasesCompletedNCT01307878Phase 3
• Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast CancerCompletedNCT01069081Phase 2
• Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal CancerStatus unknownNCT00874406Phase 4
• Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal CancerCompletedNCT00869271Phase 4
• Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal CancerStatus unknownNCT00868569Phase 4
• Simultaneous Versus Staged Resection for Initially Resectable Synchronous Rectal Cancer Liver-limited MetastasisCompletedNCT00677586Not applicable
• Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal CancerStatus unknownNCT00643877Phase 3
• Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)CompletedNCT00629148Phase 2
• Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative ResectionStatus unknownNCT00561522Phase 2/3
• Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone MetastasisCompletedNCT00524849Phase 2/3